Philips launches eV14-2v transvaginal transducer
Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026
The launch strengthens Philips' competitive position in the women's health ultrasound market, potentially driving sales growth. It may positively influence investor sentiment for Philips, though the impact is modest given the niche product segment.
Philips introduced the eV14-2v transvaginal transducer, expanding its obstetrics and gynecology ultrasound portfolio. The device is FDA 510(k) cleared and CE marked, designed to support a broad range of gynecology and early obstetrics exams. It offers a 41.7% increase in penetration, 10% improvement in 2D resolution, 15.8% wider field of view, and is 22% lighter compared to the 3D9-3v transducer. The transducer leverages PureWave crystal technology and is compatible with Philips Collaboration Live for remote consultations. It will be showcased at the 36th ISUOG World Congress. Philips highlights its commitment to advancing women's health and improving patient experience.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard